Jan 30, 2023 | Press Releases
Goal ‘to change the cancer research narrative in Africa’ by applying HDT Bio’s advanced technology to help reduce inequalities in health care PRETORIA, SOUTH AFRICA and SEATTLE, WA (January 30, 2023) – HDT Bio Corp., a developer of immunotherapies for infectious...
Nov 30, 2022 | Press Releases
UTMB will collaborate with HDT Bio Corp. and the National Institute of Allergy and Infectious Diseases’ Rocky Mountain Labs to develop vaccines against Crimean-Congo hemorrhagic fever virus (CCHFV) and Nipah virus (NiV) The 5-year $59M prototype project will develop...
Nov 7, 2022 | Press Releases
SEATTLE–HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced today it has been selected to join Blue Knight, a collaboration between Johnson & Johnson Innovation – JLABS (‘JLABS’) and the Biomedical Advanced Research...
Nov 1, 2022 | Press Releases
SEATTLE, WA (November 1, 2022) – HDT Bio Corp., a developer of immunotherapies for infectious diseases and oncology, announced today CEO Steven Reed will give a corporate presentation on Nov. 8, 3 pm, Fourth Floor, (Adams) at the BioFuture Investor Conference at the...
Aug 23, 2022 | Press Releases
The company’s saRNA vaccine technology, using its proprietary LION™ delivery system, already has proved successful in development of COVID-19 vaccines SEATTLE, WA (August 23, 2022) – HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases,...
Aug 8, 2022 | Press Releases
The antiviral product, HDT-201, will utilize company’s RNA/LION™ platform technology and ultimately will be available to the public. SEATTLE, WA (August 8, 2022) – HDT Bio Corp., a developer of immunotherapies for infectious diseases and oncology, announced today it...
